Home > Journals > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Past Issues > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2017 March;61(1) > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2017 March;61(1):108-14

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as

 

ORIGINAL ARTICLE   

The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2017 March;61(1):108-14

DOI: 10.23736/S1824-4785.16.02727-8

Copyright © 2014 EDIZIONI MINERVA MEDICA

language: English

Stable metabolic disease on FDG-PET provides information on response to endocrine therapy for breast cancer

Vibeke KRUSE 1, Christophe VAN DE WIELE 2, 3, Alex MAES 3, 4, Marleen BORMS 5, Hans POTTEL 4, Simon VAN BELLE 1, Veronique COCQUYT 1

1 Department of Medical Oncology, Ghent University Hospital, Ghent, Belgium; 2 Department of Radiology and Nuclear Medicine, University of Ghent, Ghent, Belgium; 3 Department of Nuclear Medicine, Groeninge University Hospital, Kortrijk, Belgium; 4 Subfaculty of Medicine, Catholic University of Leuven, Kortrijk, Belgium; 5 Department of Radiotherapy and Medical Oncology, Groeninge University Hospital, Kortrijk, Belgium


PDF


BACKGROUND: The aim of this study was to assess whether outcome in advanced breast cancer patients is related to metabolic response to endocrine therapy determined by fluorodeoxyglucose positron-emission tomography (FDG-PET).
METHODS: We retrospectively identified 21 consecutive breast cancer patients receiving endocrine therapy for metastatic disease (mean number of previous therapies 3.6±3.5). All patients had been evaluated with at least 2 FDG-PETs. The first scan was performed by initiation of endocrine therapy. The second scan was performed after a mean of 3.8±1.14 months. Seventy-two FDG-avid lesions were identified and followed. The mean change in SUVmax (ΔSUVmax) was calculated per patient.
RESULTS: ΔSUVmax dichotomized using the group median as cut-off (8.6%) was predictive of progression-free survival (PFS). The median PFS for the response-group (N.=10, median ΔSUVmax -20.9%) was 10.1 months. The median PFS for the progressive disease-group (N.=11, median ΔSUVmax 40.6%) was 6.7 months (log-rank testing P=0.033).
CONCLUSIONS: Our data suggest that breast cancer patients under hormonal therapy with stable disease on FDG-PET have a longer PFS when compared to non-responders. This finding is new, supporting the value of endocrine therapy among patients with advanced breast cancer.


KEY WORDS: Hormone replacement therapy - Breast neoplasms - Fluorodeoxyglucose F18 - Positron-emission tomography - Disease-free survival

top of page